Currently, many illnesses that affect millions of patients worldwide have a single diagnosis that encompasses multiple different diseases, each affecting distinct groups of patients with distinct biological causes. This often results in unique symptoms, which are driven by abnormalities in genetic circuits that differ from the drivers found in the other groups.

Vesalius' DIAMOND platform works like a prism that separates patients into therapeutically meaningful groups using artificial intelligence and machine learning to bring to light the biology underlying the clinical presentation. DIAMOND creates proprietary patient-derived experimental systems that it uses to screen and characterize drug candidates to restore these circuits to healthy functioning. This approach will reveal new paths to develop therapeutics for previously intractable diseases.

Vesalius has made significant progress identifying genetic circuits within subpopulations of patients in several difficult-to-treat diseases, providing proof-of-concept for its approach, and opening the door to many different therapeutic categories.

New algorithm enables comparisons of tumors across patients
Researchers have developed an algorithm that can take either single-cell mass cytometry data or RNA sequencing data, align it, and extract a common denominator...